Multicentre prospective observational study evaluating recommendations for mastectomy by multidisciplinary teams.
CONCLUSION: Most mastectomies are advised for large tumour to breast size ratio, but there is an inconsistency in the use of NST to downsize tumours in patients with large ER+ or HER2+ cancers. The application of standardized recommendations for NST could reduce the number of mastectomies advised by MDTs. PMID: 31691270 [PubMed - as supplied by publisher]
The objective of this study is to determine factors related with axillary downstaging and complete pathological response (CPR), and how CPR influences the decision to perform bilateral mastectomy with immediate reduction. METHODS: A retrospective analysis of breast cancer patients who had undergone neoadjuvant chemotherapy and bilateral mastectomy with immediate reduction between 2000-2018 was performed. Two groups were compared:1) CPR and 2) non-CPR. Descriptive and comparative statistical analyses are provided. RESULTS: 69 patients; 26 (37.68%) reached CPR and 43 (62.32%) non-CPR. Median follow-up of 45.3 month...
This study aimed to describe treatment patterns of patients with positive SLNs who undergo mastectomy using a large population-based database.MethodsThe NCDB was queried for cT1 –2N0 breast cancer patients treated with mastectomy between 2006 and 2014 who had 1-2 positive SLNs. Patients receiving neoadjuvant chemotherapy were excluded. Axillary management included SLN dissection (SLND) alone, axillary lymph node dissection (ALND), post-mastectomy radiation (PMRT) alone, a nd ALND + PMRT. Trends of axillary management and patient characteristics were examined.ResultsAmong 12,190 patients who met study cr...
Conclusion: Adjuvant trastuzumab was associated with higher CNS failure rate in Korean patients with HER2-enriched breast cancer. Close monitoring and reasonable approaches such as CNS penetrating HER2 blockades combined with the current standard therapy could contribute to improving intracranial tumor control and quality of life in patients with CNS metastasis from HER2-enriched breast cancer. PMID: 30941239 [PubMed]
CONCLUSIONSFor patients with Luminal/HER2 negative breast cancer, the combination of the imaging features of the tumor and the mammary gland, obtained with 18F-FDG PET-CT at baseline and after the first cycle of NAC, may allow the physician to evaluate the probability of BCS.
CONCLUSION: This is one of the largest comprehensive data from a single center in India. Majority of our patients are younger in age and have advanced disease. TNBC and HER2/neu positive breast cancer are more common in our population.
CONCLUSION: BCS after NACT is feasible and safe in terms of LRR, DFS and OS, if patients are properly studied and selected. Indication to BCS after NACT needs of a multidisciplinary assessment considering clinical staging, biological characteristics, the radiological response pattern and the expected concordance between imaging and histology. KEY WORDS: Breast Cancer, Breast-conserving surgery, Neoadjuvant chemotherapy. PMID: 30569900 [PubMed - in process]
CONCLUSION: Although there was a significantly higher number of patients achieving pCR among HR-/HER2+ subtype compared to other BC subtypes, this did not translate into improvement in long-term disease outcome of these patients. PMID: 30570847 [PubMed - in process]
Neoadjuvant treatment for early breast cancer (EBC) has been historically proposed to enable breast-conserving surgery in stage II-III, in particular for triple negative and HER2-positive EBC, although a recently published meta-analysis suggests that this strategy could fail in reducing the mastectomy rate [1-3]. Interestingly, in the last few years, this setting has become an ideal scenario for drug development and biomarker discovery, with an in vivo evaluation of tumor dynamic response as early outcome [4-6].
In conclusion, sufficient evidence is now available to suggest that breast conservation after neoadjuvant chemotherapy is safe and effective for selected patients. Though neoadjuvant chemotherapy may increase the complexity of breast conservative treatment, a close collaboration between a multidisciplinary team and use of oncoplastic surgical techiques permit to optimize oncological and cosmetis outcomes. PMID: 30352955 [PubMed - in process]